Wide Ranks

FDMT

4D Molecular Therapeutics, Inc.

7.87

Top Statistics
Market Cap 363 M Forward PE -2.18 Revenue Growth -100.00 %
Current Ratio 0.00 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months 21400.71
Profitability
Profit Margins 0.00 % Operating Margins -1704400.00 %
Balance Sheet
Total Cash Total Cash Per Share Total Debt
Total Debt To Equity 2.32 Current Ratio 0.00 Book Value Per Share 7.15
All Measures
Short Ratio 1017.00 % Message Board Id finmb_272879653 Shares Short Prior Month 9 M
City EmeryVille Uuid 3c71667a-4f1e-3d28-8cb0-26ab7aa9e925 Previous Close 7.50
First Trade Date Epoch Utc 1 B Book Value 7.15 Volume 1 M
Price To Book 1.10 Fifty Two Week Low 7.32 Total Revenue 17000
Shares Short Previous Month Date 1 B Target Median Price 40.00 Max Age 86400
Recommendation Mean 1.92 Sand P52 Week Change 0.3133 Operating Margins -1704400.00 %
Target Mean Price 45.64 Net Income To Common -143480000 Short Percent Of Float 0.1762
Implied Shares Outstanding 51 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0391 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 7.50 Target Low Price 8.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 9.03 Open 7.51
Dividend Yield 0.00 % State CA Time Zone Short Name EST
Trailing Eps -2.85 Day Low 7.44 Address1 5858 Horton Street
Shares Outstanding 46 M Price Hint 2 Target High Price 82.00
Website https://www.4dmoleculartherapeutics.com 52 Week Change -0.3813 Average Volume 900260
Forward Eps -3.29 Recommendation Key buy Compensation As Of Epoch Date 1 B
Is_sp_500 False Regular Market Day High 7.89 Profit Margins 0.00 %
Debt To Equity 2.32 Fifty Two Week High 36.25 Day High 7.89
Shares Short 7 M Regular Market Open 7.51 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth -100.00 % Shares Percent Shares Out 0.1693
Currency USD Time Zone Full Name America/New_York Market Cap 363 M
Is_nasdaq_100 False Zip 94608 Quote Type EQUITY
Industry Biotechnology Long Name 4D Molecular Therapeutics, Inc. Regular Market Day Low 7.44
Held Percent Institutions 1.15 Current Price 7.87 Address2 Suite 455
Financial Currency USD Current Ratio 0.00 Industry Disp Biotechnology
Number Of Analyst Opinions 11 Country United States Float Shares 25 M
Two Hundred Day Average 19.63 Price To Sales Trailing12 Months 21400.71 Forward PE -2.18
Regular Market Volume 1 M Ebitda -163692000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States.

The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema.

The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial.

In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development.

The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.

V.

; and Cystic Fibrosis Foundation.

4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.